142 related articles for article (PubMed ID: 35689106)
21. Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH.
Guerrios-Rivera L; Howard LE; Klaassen Z; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Freedland SJ
Urology; 2021 Mar; 149():181-186. PubMed ID: 33189734
[TBL] [Abstract][Full Text] [Related]
22. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
[TBL] [Abstract][Full Text] [Related]
23. Comparison of pathological and biochemical outcomes after radical prostatectomy in Korean patients with serum PSA ranges.
Lee HW; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
J Korean Med Sci; 2015 Mar; 30(3):317-22. PubMed ID: 25729256
[TBL] [Abstract][Full Text] [Related]
24. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
25. Nomogram Predicting Adverse Pathology Outcome on Radical Prostatectomy in Low-Risk Prostate Cancer Men.
Nasri J; Barthe F; Parekh S; Ratnani P; Pedraza AM; Wagaskar VG; Olivier J; Villers A; Tewari A
Urology; 2022 Aug; 166():189-195. PubMed ID: 35263642
[TBL] [Abstract][Full Text] [Related]
26. Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study.
Amini E; Palmer TC; Cai J; Lieskovsky G; Daneshmand S; Djaladat H
World J Urol; 2018 Aug; 36(8):1233-1239. PubMed ID: 29536157
[TBL] [Abstract][Full Text] [Related]
27. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Becker A; Chun FKH; Karakiewicz PI
Prostate; 2022 May; 82(6):687-694. PubMed ID: 35188982
[TBL] [Abstract][Full Text] [Related]
28. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
29. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
30. SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy.
Faisal FA; Kaur HB; Tosoian JJ; Tomlins SA; Schaeffer EM; Lotan TL
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):552-559. PubMed ID: 30850708
[TBL] [Abstract][Full Text] [Related]
31. Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
Wilkins LJ; Tosoian JJ; Reichard CA; Sundi D; Ranasinghe W; Alam R; Schwen Z; Reddy C; Allaf M; Davis JW; Chapin BF; Ross AE; Klein EA; Nyame YA
Cancer; 2021 May; 127(9):1425-1431. PubMed ID: 33721334
[TBL] [Abstract][Full Text] [Related]
32. The impact of surgical downgrading on prostate cancer recurrence: systematic review and analysis of a multiethnic population.
Zhu D; Shyr W; Toker M; Fram E; Cheng J; Kovac EZ; Agalliu I; Aboumohamed A; Watts KL
World J Urol; 2022 Mar; 40(3):709-718. PubMed ID: 34850269
[TBL] [Abstract][Full Text] [Related]
33. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
[TBL] [Abstract][Full Text] [Related]
34. High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy.
Porcaro AB; Petroziello A; Brunelli M; De Luyk N; Cacciamani G; Corsi P; Sebben M; Tafuri A; Tamanini I; Caruso B; Ghimenton C; Monaco C; Artibani W
Urol Int; 2016; 96(4):470-8. PubMed ID: 26845458
[TBL] [Abstract][Full Text] [Related]
35. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
[TBL] [Abstract][Full Text] [Related]
36. Increasing rate of pathologic upgrading in low risk prostate cancer patients in the active surveillance era.
Davaro F; Weinstein D; Wong R; Siddiqui S; Hinyard L; Hamilton Z
Can J Urol; 2022 Apr; 29(2):11059-11066. PubMed ID: 35429423
[TBL] [Abstract][Full Text] [Related]
37. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
38. Preoperative Statin Use at the Time of Radical Prostatectomy Is Not Associated With Biochemical Recurrence or Pathologic Upgrading.
Lyon TD; Turner RM; Yabes JG; Woldemichael E; Davies BJ; Jacobs BL; Nelson JB
Urology; 2016 Nov; 97():153-159. PubMed ID: 27516122
[TBL] [Abstract][Full Text] [Related]
39. The prognostic impact of downgrading and upgrading from biopsy to radical prostatectomy among men with Gleason score 7 prostate cancer.
Jang WS; Koh DH; Kim J; Lee JS; Chung DY; Ham WS; Rha KH; Choi YD
Prostate; 2019 Dec; 79(16):1805-1810. PubMed ID: 31483062
[TBL] [Abstract][Full Text] [Related]
40. Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
Wong LM; Tang V; Peters J; Costello A; Corcoran N
BJU Int; 2016 Apr; 117 Suppl 4():82-7. PubMed ID: 27094971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
